“脱欧”对药品研发的监管影响
Regulatory Consequences of "Brexit" for the Development of Medicinal Products.
作者信息
Jackson E L, Feldschreiber P, Breckenridge A
机构信息
London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK.
4, New Square Lincoln's Inn, London, WC2A 3RT, UK.
出版信息
Clin Pharmacol Ther. 2017 Aug;102(2):183-184. doi: 10.1002/cpt.706. Epub 2017 May 27.
The United Kingdom voted in a referendum in June 2016 to leave the European Union (EU) after 45 years of membership. Among the many political, social, and scientific consequences are those for the regulation of health care products. No longer will the efficacy, safety, and quality of medicines in the United Kingdom be subject to an EU regulatory framework. The European Medicines Agency (EMA), which is currently located in London, will move elsewhere in Europe. The pharmaceutical industry will reassess its commitment to the UK health scene.
2016年6月，英国在全民公投中投票决定脱离欧盟，结束了其长达45年的成员国身份。这一举动带来了诸多政治、社会和科学影响，其中就包括对医疗保健产品监管方面的影响。英国药品的疗效、安全性和质量将不再受欧盟监管框架的约束。目前位于伦敦的欧洲药品管理局（EMA）将迁至欧洲其他地方。制药行业也将重新评估其对英国医疗领域的投入。
Zotero 插件